Latest News and Press Releases
Want to stay updated on the latest news?
-
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
-
Portage Biotech Inc. received notice from The Nasdaq Stock Market, LLC, indicating that the Company has regained compliance.
-
Portage Biotech and Compedica Stock-for-Stock Exchange
-
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
-
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
-
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative...
-
Portage Biotech receives extension of time to attain compliance with stock exchange continued listing requirements
-
On January 29, 2025, Portage Biotech Inc. (the “Company”) completed the sale of 524,390 ordinary shares for aggregate proceeds of US$2,150,000.
-
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
-
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd